Novel PD therapy to launch in Nordic region

2 October 2019

Swedish startup Lobsor Pharmaceuticals expects to complete registration in the Nordic region for its lightweight Parkinson’s disease therapy Lecigon (levodopa/carbidopa/entacapone) this month.

Under the European Mutual Recognition Procedure (MRP), the firm will be able to commence commercialization in Denmark, Finland and Norway,  following approval in Sweden in October 2018.

The product could shake up a market dominated by AbbVie, whose Duodopa (levodopa/carbidopa) product is now more than a decade old.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Biotechnology